Pharma Promotion / Canada / Industry-association papers
Canada ── Industry-association papers
53 records since 1990, judged by Jev for relevance, jurisdiction, type and importance.
Primary documents
- Industry-association papers / Promotion codesInnovative Medicines CanadaCanadian consensus framework for ethical collaboration
- Industry-association papers / TransparencyInnovative Medicines CanadaVoluntary disclosure of payments
- Industry-association papers / Pricing & market accessInnovative Medicines Canada2026 Cost drivers report
- Industry-association papers / Health policyInnovative Medicines CanadaThe value of the innovative pharmaceutical industry – A report summary
- Industry-association papers / Pricing & market accessInnovative Medicines Canada2025 Cost drivers report
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaIncreasing access to innovative medicines
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaIncreasing access to innovative medicines
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaIncreasing access to innovative medicines
- Industry-association papers / Clinical trials & R&DInnovative Medicines CanadaCanada’s innovative pharmaceutical industry
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaCanadian drug access pathway
- Industry-association papers / Clinical trials & R&DInnovative Medicines CanadaThe Canadian research & development pharmaceutical sector 2021
- Industry-association papers / Health policyInnovative Medicines CanadaOpen letter
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaLetter to the standing committee on public accounts
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaLetter to Dr. Mélanie Bourassa Forcier, Acting chairperson, Patented Medicine Prices Review Board (PMPRB)
- Industry-association papers / Promotion codesInnovative Medicines CanadaCompetition guidelines
- Industry-association papers / Promotion codesInnovative Medicines CanadaCompetition guidelines regarding meetings
- Industry-association papers / Health policyInnovative Medicines CanadaPre-budget submission 2026
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaIncreasing access to innovative medicines
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaIncreasing access to innovative medicines
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaIncreasing access to innovative medicines
- Industry-association papers / Health policyInnovative Medicines CanadaSubmission to the Government of Canada’s consultation on the review of the Canada – United States -Mexico agreement
- Industry-association papers / Health policyInnovative Medicines CanadaRare disease framework for Alberta
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaPublic reimbursement timelines: a pandemic snapshot
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaDownload all
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaInnovative agreements framework
- Industry-association papers / OtherInnovative Medicines CanadaFrenchFrançais
- Industry-association papers / Health policyInnovative Medicines CanadaPrivate market policy summit report, 2025
- Industry-association papers / Clinical trials & R&DInnovative Medicines CanadaClinical trials in Canada: Insights and implications
- Industry-association papers / Health policyInnovative Medicines CanadaThe Canadian research and development pharmaceutical sector, 2022
- Industry-association papers / Health policyInnovative Medicines CanadaIssues and opportunities to modernize private drug plan sustainability 2024
- Industry-association papers / Clinical trials & R&DInnovative Medicines CanadaThe Canadian research and development pharmaceutical sector, 2021
- Industry-association papers / Clinical trials & R&DInnovative Medicines CanadaClinical trials research note
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaCost drivers report 2023
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaIncreasing access to innovative medicines
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaReflections on a potential federal drug formulary: Medicines industry response to CDA consultation
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaIMC response to the PMPRB’s March 2025 guidelines consultation
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaIncreasing access to innovative medicines
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaTwo years is too long – Understanding Canada’s drug access pathway
- Industry-association papers / Clinical trials & R&DInnovative Medicines CanadaClinical trials in Canada – Numbers
- Industry-association papers / Health policyInnovative Medicines CanadaHealthcare spending in Canada
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaExplaining public reimbursement delays for new medicines for Canadian patients
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaEarly signs of negative impacts for patients of Health Canada pharmaceutical pricing reforms
- Industry-association papers / Health policyInnovative Medicines CanadaHow would a single-payer publicly funded national pharmacare program affect the quality of access to medicines for Canadian patients?
- Industry-association papers / Health policyInnovative Medicines CanadaComparison of Canadian and non-Canadian pharmaceutical IP regimes
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaAddendum to IMC submission on drugs for rare diseases
- Industry-association papers / Health policyInnovative Medicines CanadaTowards a value-based and pan-Canadian rare disease strategy
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaIMC Response to the PMPRB’s 2024 discussion guide on the board’s guidelines
- Industry-association papers / Health policyInnovative Medicines CanadaSubmission on proposed patent term adjustment (PTA) regulations
- Industry-association papers / Clinical trials & R&DInnovative Medicines CanadaIMC response to consultation on scientific research and experimental development
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaIMC response to the PMPRB’s 2023 scoping paper for the consultations on the board’s guidelines
- Industry-association papers / Health policyInnovative Medicines CanadaSubmission on consultation regarding patent term adjustment (PTA) regulations
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaIMC response to the PMPRB’s 2023 interim guidance consultation
- Industry-association papers / Pricing & market accessInnovative Medicines CanadaThe Suspension and reformulation of the PMPRB guidelines is urgently required: IMC response to PMPRB 2022 guidelines proposals